泮托拉唑、克拉霉素和阿莫西林一周三联疗法治疗十二指肠溃疡患者幽门螺杆菌感染的疗效和耐受性
Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer.
作者信息
Labenz J, Tillenburg B, Weismüller J, Lütke A, Stolte M
机构信息
Department of Internal Medicine and Gastroenterology, Elisabeth Hospital Essen, Germany.
出版信息
Aliment Pharmacol Ther. 1997 Feb;11(1):95-100. doi: 10.1046/j.1365-2036.1997.130301000.x.
BACKGROUND
Previous studies have shown that one-week triple therapy consisting of omeprazole, clarithromycin and amoxycillin may cure Helicobacter pylori infection in the vast majority of patients. The present study was designed to test the hypothesis that a triple therapy with pantoprazole, clarithromycin and amoxycillin cures the infection in > or = 80% of duodenal ulcer patients infected with H. pylori.
METHODS
In an open two-centre study, 60 duodenal ulcer patients were treated with pantoprazole 40 mg b.d., clarithromycin 500 mg b.d. and amoxycillin 1 g b.d. for 1 week. During the second week patients received pantoprazole 40 mg once in the morning. We assessed H. pylori infection before treatment and 4 weeks after cessation of the study medication by a rapid urease test, histology after Warthin-Starry stain and a 13C-urea breath test.
RESULTS
Sixty patients (42 males, mean age 47.4 years) entered the trial. All patients were infected with H. pylori. One patient was withdrawn from the study because of allergy to penicillin and six patients were protocol violators. H. pylori infection was cured in 47 out of 53 patients who completed the trial according to the protocol (89%; 95% CI: 80-97%) and in 49 of 60 patients included in the trial (82%; 95% CI: 72-92%). Four weeks after the last administration of study drugs, 55 out of 60 ulcers had healed (92%). Twenty-nine patients reported 51 adverse events that were mostly mild to moderate.
CONCLUSIONS
One-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin is a simple and effective approach to the cure of H. pylori infection in patients with duodenal ulcer. In those patients who took the drugs as prescribed the H. pylori cure rate was 89%, with the lower 95% confidence limit being 80%.
背景
既往研究表明,由奥美拉唑、克拉霉素和阿莫西林组成的一周三联疗法可治愈绝大多数幽门螺杆菌感染患者。本研究旨在验证以下假设:泮托拉唑、克拉霉素和阿莫西林三联疗法可治愈≥80%的幽门螺杆菌感染十二指肠溃疡患者。
方法
在一项开放性双中心研究中,60例十二指肠溃疡患者接受泮托拉唑40mg每日2次、克拉霉素500mg每日2次和阿莫西林1g每日2次治疗1周。在第二周,患者于早晨服用一次40mg泮托拉唑。我们在治疗前以及研究药物停用4周后,通过快速尿素酶试验、Warthin-Starry染色后的组织学检查以及13C-尿素呼气试验评估幽门螺杆菌感染情况。
结果
60例患者(42例男性,平均年龄4岁)进入试验。所有患者均感染幽门螺杆菌。1例患者因对青霉素过敏退出研究,6例患者违反方案。按照方案完成试验的53例患者中,47例(89%;95%CI:80 - 97%)幽门螺杆菌感染得到治愈,纳入试验的60例患者中49例(82%;95%CI:72 - 92%)治愈。最后一次服用研究药物4周后,60例溃疡中有55例(92%)愈合。29例患者报告了51次不良事件,大多为轻至中度。
结论
由泮托拉唑、克拉霉素和阿莫西林组成的一周三联疗法是治愈十二指肠溃疡患者幽门螺杆菌感染的一种简单有效的方法。在那些按规定服药的患者中,幽门螺杆菌治愈率为89%,95%置信区间下限为80%。